The first question in a transfer discussion is not whether a line is “continuous.” It is where continuity begins and ends, which steps remain batch, how material is tracked between them, and what evidence demonstrates control through normal operation and transient events.

1. Define the process boundary before comparing technologies

ICH Q13 covers drug substances and drug products and describes multiple modes: some operations may remain batch while selected steps are connected in a continuous mode, or more operations may be integrated. The guideline focuses on integrated aspects when two or more unit operations are directly connected; its examples are illustrative rather than a required design. [1]

For a proposed transfer, map each operation, input and output, intermediate hold, surge capacity, interface, sampling point, diversion point and batch-definition rule. Record which steps are actually in scope, what is outside the continuous train, and who owns the controls at each interface. Avoid treating “continuous” as a binary maturity score.

2. Test the transfer evidence, not only the equipment list

A useful technical package links material attributes and their variability to process performance and product quality. It explains the intended operating ranges, relevant equipment configuration, transfer effects, process models and the rationale for control limits. A receiving team should be able to reproduce the decision logic, not merely receive a folder of batch records and model files.

  • Process description, unit-operation boundaries and justified batch definition.
  • Material characterization and evidence that input variability is understood.
  • Residence-time distribution (RTD) and material traceability across connected operations.
  • Model assumptions, intended use, lifecycle ownership and validation implications.
  • Defined transfer protocols, acceptance criteria, deviation handling and knowledge owners.

3. Challenge start-up, shutdown and disturbances

ICH Q13 calls out planned transients such as start-up, shutdown and pauses as well as unplanned disturbances. A transfer assessment should ask how these events affect the material stream, how potentially nonconforming material is detected and segregated, and what criteria determine the beginning and end of diversion and the restart of collection. RTD and process dynamics help connect a disturbance at one point in the train to material elsewhere in the system. [1]

Request representative challenge scenarios and examine whether operator actions, alarm response, sampling, diversion logic and documentation are consistent with the process design. The relevant scenarios are product- and system-specific; this article does not prescribe universal setpoints or acceptance limits.

4. Connect process controls to trustworthy data

Monitoring and control should support a defined state of control. Where process analytical technology or other real-time measurements are used, establish what each signal represents, its limitations, calibration and maintenance approach, data gaps and how the signal triggers a decision. Review computerized systems, audit trails, time synchronization, access controls, backup and change control as part of the data-integrity assessment—not as a separate IT appendix.

For a contractor relationship, the parties should agree who owns system configuration, method lifecycle, alarm and model changes, investigation records, batch disposition inputs and retention of raw and processed data. Responsibilities belong in the quality system and quality agreement; contract wording does not replace technical evidence or regulatory responsibilities.

5. Plan validation, continued verification and regulatory change management

ICH Q13 addresses process validation, continued process verification, stability, lifecycle management and the conversion of an existing batch process to continuous manufacturing. The assessment should identify the target markets, submission commitments, change classification, comparability or stability evidence, validation approach and the regulator-specific communication or approval steps that may apply. Confirm these with the responsible regulatory experts and authorities before execution. [1]

WHO's 2026 document is explicitly titled “points to consider.” It complements ICH Q13 and offers a practical manufacturer-focused review of continuous pharmaceutical manufacturing. It is not a site certification, product approval or substitute for jurisdiction-specific requirements. Its examples do not establish a sterile-injectable platform at any named company. [2]

What a 2026 Nature Portfolio study adds—and does not add

A peer-reviewed Scientific Reports paper published on 1 September 2026 proposes a dynamic operability index for campaign-mode continuous pharmaceutical manufacturing under uncertainty. The authors demonstrate the method in two examples, including campaign continuous aspirin crystallization. Nature Portfolio states that the accessible early version is citable but subject to later edits. This is a research method that may inform discussion of transient operation and on-specification production—not a regulator-endorsed metric, universal validation standard, or proof of commercial performance across dosage forms and sites. [3]

A practical assessment checklist

  1. Is the process boundary explicit, including all batch/continuous interfaces and batch definition?
  2. Are material attributes, variability, RTD and traceability supported by process-specific evidence?
  3. Are start-up, shutdown, pause and disturbance scenarios linked to sampling, diversion and collection criteria?
  4. Do monitoring, control strategy, computerized systems and data-integrity controls have defined owners and lifecycle controls?
  5. Are validation, continued process verification, stability and planned operating ranges justified?
  6. Have receiving-site fit, technical-transfer acceptance criteria, quality responsibilities and target-market regulatory steps been independently verified?

Claim boundary
This is a general due-diligence framework based on public guidance and literature. It does not describe a customer project or assert that Hainan Hailing Chemipharma, Steven Li, or any named manufacturing site operates continuous manufacturing or has completed a related technology transfer. Supplier, product, site and regulatory claims require their own documentary verification.

Frequently asked questions

Does continuous manufacturing mean every manufacturing step must run continuously?

No. ICH Q13 describes modes in which some unit operations are batch while others are connected and continuous, as well as more fully integrated arrangements. The exact boundary, interfaces and batch definition should be defined for the specific process.

What should a technology-transfer assessment examine first?

Start with process boundaries and product knowledge, then assess material and residence-time traceability, start-up and shutdown, disturbances and diversion, monitoring and control, computerized-system/data-integrity controls, validation, continued process verification, stability and change-management requirements.

Does WHO's 2026 document establish that a sterile injectable site can run continuous manufacturing?

No. WHO's document provides points to consider and does not demonstrate capability at any specific company or site. Its examples and the evidence available for a proposed dosage form, unit operation and market must be checked separately. This page makes no claim that Hainan Hailing or a named site operates continuous manufacturing.

Does the 2026 Nature Portfolio paper prove that its operability index is validated for every medicine?

No. The paper introduces a dynamic index and demonstrates it with two examples, including campaign continuous aspirin crystallization. It is a research method, not a universal qualification, regulator-endorsed metric or proof of commercial performance across products and facilities.

Authoritative sources

  1. ICH Q13: Continuous Manufacturing of Drug Substances and Drug Products (final, adopted 16 November 2022)
  2. WHO TRS 1067, Annex 2: Points to Consider in Continuous Manufacturing of Pharmaceutical Products (9 June 2026)
  3. Khamda, Sahlodin & Fallah, “A new dynamic operability index based on on-specification production for continuous pharmaceutical manufacturing under uncertainty,” Scientific Reports (published 1 September 2026)

Research note: Scientific Reports is part of the Nature Portfolio. The cited paper is peer-reviewed and open access; its early version may be revised before the final Version of Record. The examples are not evidence of adoption by a regulator or qualification of a specific supplier, product or facility.

For general business and educational information only; not legal, regulatory, quality, engineering or medical advice. Confirm requirements for each product, process, facility and target market with qualified experts and the responsible authorities.